La cadena de opciones muestra datos clave de las opciones de acciones de Myriad Genetics a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Myriad Genetics..

Myriad Genetics (NASDAQ:MYGN) Bolsa, Cadena de Opciones

Myriad Genetics

Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.

Myriad Genetics Inc

Piper Sandler analyst John Peterson maintains Myriad Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>) with a Neutral and lowers the price target from $24 to $14.

News

Price Target

Analyst Ratings

MYGN

Piper Sandler Maintains Neutral on Myriad Genetics, Lowers Price Target to $14

<a href="https://www.globenewswire.com/Tracker?data=Yp5pZUGkmgWeCrtxie73Rg99tLVrq9zyIeAPwL55Zi3zAnZ1OcdzY0RrblSyNb0MPiR5A57Q1ZuOsHRgoii9dA==">Myriad Genetics, Inc</a>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>), a leader in genetic testing and precision medicine, today announced it will unveil groundbreaking research at the annual Society for Maternal-Fetal Medicine Conference (SMFM). The company's "Fetal fraction amplification enables accurate prenatal cell-free DNA (cfDNA) screening at eight weeks gestation" study was awarded SMFM's "Dru Carlson Memorial Award for Best Research in Ultrasound and Genetics."
The study found that <a href="https://www.globenewswire.com/Tracker?data=Zw1Txz9m0LZemotcUmoj_v4kBiRmqbB-RUXGk-7uly0p0sSWGcfafv_HzLGf5EPEIJIlrTR9pV_bbG9z2q2U9PGDHRnDbSZWSwBJ-VPXi34Vb6Rp0eReke0e1LV0ES-BvwDbTaVymgloiRfAhMMeI0SpUcs8LyyvgkqsUc_DEWwSrA58u3lNpgeV5zyiKwUl">Prequel&#xAE;&nbsp;Prenatal Screen with AMPLIFY&#x2122;&nbsp;technology</a> enables reliable results as early as eight-weeks' gestation. Typically, prenatal cell-free DNA (pcfDNA) screening is offered beginning at nine to 10 weeks' gestation. At earlier gestational ages, the proportion of placental cfDNA, referred to as the fetal fraction (FF), is often too low to allow for confident analysis. Prequel with AMPLIFY can overcome this limitation by increasing the FF. This study found that by using Prequel with AMPLIFY, the average FF was 12.5%, with a no-call rate of less than 0.5% between eight and 10 weeks of gestation.

Biotech

General

Myriad Genetics Announces Prenatal DNA Screening Research; Prequel With AMPLIFY Enables Reliable Results At 8 Weeks Gestation With 12.5% Fetal Fraction And Less Than 0.5% No-Call Rate

Goldman Sachs analyst Matthew Sykes maintains Myriad Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>) with a Buy and lowers the price target from $29 to $18.

Goldman Sachs Maintains Buy on Myriad Genetics, Lowers Price Target to $18

Myriad Genetics Announces Publication Of Hereditary Cancer Risk Assessment Program Study In Obstetrics & Gynecology

In the preceding three months, 6 analysts have released ratings for Myriad Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>), presenting a wide array of perspectives from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Myriad Genetics, presenting an average target of $19.5, a high estimate of $24.00, and a low estimate of $13.00. This current average represents a 23.23% decrease from the previous average price target of $25.40. 
<img src="https://www.benzinga.com/files/images/story/2025/1737061230_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Myriad Genetics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mason Carrico</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Equal-Weight</td>
<td>$20.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Derik De Bruin</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$13.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Lu Li</td>
<td>UBS</td>
<td>Announces</td>
<td>Neutral</td>
<td>$18.00</td>
<td>-</td>
</tr>
<tr>
<td>Puneet Souda</td>
<td>Leerink Partners</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$21.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Tejas Savant</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$21.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>John Peterson</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$24.00</td>
<td>$30.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Myriad Genetics. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Myriad Genetics compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Myriad Genetics's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Myriad Genetics's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/MYGN/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Myriad Genetics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Discovering Myriad Genetics: A Closer Look</h2>
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.
<h3>Myriad Genetics: A Financial Overview</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Positive Revenue Trend: Examining Myriad Genetics's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 11.15% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -10.36%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Myriad Genetics's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -3.0%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Myriad Genetics's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of -2.04%, the company showcases efficient use of assets and strong financial health.
Debt Management: With a high debt-to-equity ratio of 0.2, Myriad Genetics faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>The Significance of Analyst Ratings Explained</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Demystifying Myriad Genetics: Insights From 6 Analyst Reviews

Stephens &amp; Co. analyst Mason Carrico reiterates Myriad Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>) with a Equal-Weight and maintains $20 price target.

Reiteration

Stephens & Co. Reiterates Equal-Weight on Myriad Genetics, Maintains $20 Price Target

Guidance

Myriad Genetics Sees FY25 Adj. EPS $0.07-$0.11 Vs $0.08 Est.; Revenue $840M-$860M Vs $876.702M Est.

Myriad Genetics Sees Prelim. Q4 Adj. EPS $0.03-$0.04 Vs $0.03 Est.; Revenue $209M-$211M Vs $212.873M Est.

Under the agreement, Storm will act as an ambassador for the Myriad Genetics Breast Cancer Risk Assessment Program featuring the <a href="https://www.globenewswire.com/Tracker?data=e3VsfxUbo-yZkKbrkPomsnLaoTxIULLUg8SGhzOUD3LZsVTnph0ap0ONCJT2yjG7Ru0ZDySSBGuiWyqIAOc679R1p4wjBMWp_qS-Qp2fX0WOqAyNh_GjNdsmfUCND9P7KafrTRXVKCgUhT3KL4uAZSO2gzMV4eblYoFnZYFyHHH79mO2VhGLi_cscUCakM-H">MyRisk&#xAE; with RiskScore&#xAE; Hereditary Cancer Test</a>, the first and industry-leading hereditary cancer test and polygenic risk prediction test for all ancestries. She will promote the importance of collecting a detailed family health history for cancer and understanding the associated cancer risks.
 &nbsp;

Reported Earlier, Myriad Genetics Signs Agreement With Hannah Storm To Highlight Importance Of Knowing Family Cancer Risk

The University of Texas MD Anderson Cancer Center and <a href="https://www.globenewswire.com/Tracker?data=uO4LOlwHxRiA3mIMJWKatVr7_GxQ0-d6AnrfabhLUKvu7R3iBIL8bfDg5fkj__RbKKRZMXEHird6NEZ9zn4OT7F8jil8dFHi13ElO6qS-aYF57bEtefPzhtmfZsb5fOchjaXm8cJF__sGeNiRTrAviJOC9slJu8FvlEkPjkKAGQ3A6vV1BMwR0eRn3gBraW53iQ2G68NGkKwu8hB-Ot-8eAuEl-NDJkKpyhrnIGBLLIrYaW3NeVAiJ0fD-adKku_fmadT6XWWmK0Zl7M3v63jx8NaA674H7P5ZjJdREVeDJMpHt5zNfHJ4nSvQG7zzF2iDw3dJiTSU5ma5qEXnkeblE6Idao_-NOg-G8BU3QosujovYtAsOUBfl3jwVW8GJ7">Myriad Genetics, Inc</a><a href="https://www.globenewswire.com/Tracker?data=ktTiZ9Tjy05IzKzxsQfwBlVlk_QPFq25H79djQExaqEL79wloeNCiyz-cOqVoz1vx1WJtIgyd9kvjw4io0DCIBhhkejIqRASZdZFVFwOQbP4RYzwuq1474t9SWtpCX1FVsP3MOwTB3HP65-3n0biZ0Kob3pAPuvkF93lq5MRSnst-sE4VaEnkYXr3OYHCU6SqBny9PpRvilrkoxg7vMd_sfRk7cU_V6NPigYaEa96Nqq22i9drKiogA43Brzj_rcnfL7N9Qw6xwTNiN-G6BDQN8nDlgqx9h0nyVQ3hVl3XyJYA9e7NlSClDO_ooFG4tigVXPgQaW03v-7bkj8ApvbCPn7yUNl7KA6zUVeG37u5c=">.</a> today announced a five-year strategic alliance to accelerate the clinical evaluation and development of Myriad's molecular residual disease (MRD) assay.
This strategic alliance brings together the longstanding oncology diagnostic experience of Myriad Genetics and the clinical and translational research expertise of MD Anderson to create a portfolio of studies to evaluate the clinical validity and utility of Myriad's Precise MRD.

The University Of Texas MD Anderson Cancer Center And Myriad Genetics Announce A 5-Year Strategic Alliance To Accelerate The Clinical Evaluation And Development Of Myriad's Molecular Residual Disease Assay

B of A Securities analyst Derik De Bruin maintains Myriad Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>) with a Underperform and lowers the price target from $15 to $13.

B of A Securities Maintains Underperform on Myriad Genetics, Lowers Price Target to $13

Reported Earlier, Myriad Genetics Engages Unitedhealthcare On Pharmacogenetic Testing Policy, Seeks Continued Access To Genesight In 2025

UBS analyst Lu Li initiates coverage on Myriad Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>) with a Neutral rating and announces Price Target of $18.

Initiation

UBS Initiates Coverage On Myriad Genetics with Neutral Rating, Announces Price Target of $18

In the preceding three months, 4 analysts have released ratings for Myriad Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>), presenting a wide array of perspectives from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Myriad Genetics, revealing an average target of $24.5, a high estimate of $32.00, and a low estimate of $21.00. Highlighting a 20.12% decrease, the current average has fallen from the previous average price target of $30.67. 
<img src="https://www.benzinga.com/files/images/story/2024/1733756610_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
A clear picture of Myriad Genetics's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Puneet Souda</td>
<td>Leerink Partners</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$21.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Tejas Savant</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$21.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>John Peterson</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$24.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Tejas Savant</td>
<td>Morgan Stanley</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$32.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Myriad Genetics. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Myriad Genetics compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Myriad Genetics's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Myriad Genetics's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/MYGN/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Myriad Genetics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>All You Need to Know About Myriad Genetics</h2>
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.
<h3>Myriad Genetics: A Financial Overview</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining Myriad Genetics's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 11.15% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Myriad Genetics's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -10.36% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Myriad Genetics's ROE stands out, surpassing industry averages. With an impressive ROE of -3.0%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Myriad Genetics's ROA stands out, surpassing industry averages. With an impressive ROA of -2.04%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: With a below-average debt-to-equity ratio of 0.2, Myriad Genetics adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Analyst Ratings: Simplified</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Myriad Genetics Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Morgan Stanley analyst Betsy Graseck downgraded the rating for Bank of America Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>) from Overweight to Equal-Weight but raised the price target from $48 to $55. Bank of America shares closed at $46.75 on Friday. See how other analysts view this stock.</li>
<li>Leerink Partners analyst Puneet Souda downgraded Myriad Genetics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>) from Outperform to Market Perform and slashed the price target from $30 to $21. Myriad Genetics shares closed at $15.13 on Friday. <a href="https://www.benzinga.com/quote/MYGN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies analyst Michael Yee downgraded the rating for Biogen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) from Buy to Hold and lowered the price target from $250 to $180. Biogen shares closed at $157.78 on Friday. See how other analysts view this stock.</li>
<li>B of A Securities analyst Vivek Arya downgraded Advanced Micro Devices, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) from Buy to Neutral and lowered the price target from $180 to $155. AMD shares closed at $138.59 on Friday. <a href="https://www.benzinga.com/quote/AMD/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan analyst Sandeep Deshpande downgraded the rating for STMicroelectronics N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STM#NYSE">STM</a>) from Overweight to Neutral. STMicroelectronics shares closed at $26.43 on Friday. <a href="https://www.benzinga.com/quote/STM/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying AMD stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="616" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/09082137/image-64-1024x616.png" alt="" class="wp-image-683191" style="width:572px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/09082137/image-64-1024x616.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/09082137/image-64-300x180.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/09082137/image-64-768x462.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/09082137/image-64.png 1093w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/12/42380712/how-to-earn-500-a-month-from-oracle-stock-ahead-of-q2-earnings">How To Earn $500 A Month From Oracle Stock Ahead Of Q2 Earnings</a></li>
</ul>

Downgrades

Pre-Market Outlook

Markets

Trading Ideas

BIIB

This AMD Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday

<a href="https://www.globenewswire.com/Tracker?data=5-k5eubo2VFoIyB3xKrVhFk-h4OlDTL63c3QCYNW6ZNnrP_6rLZ0ZnI8znKwvLF8wmnZfytv5bHFsG2VO7nicQ==">Myriad Genetics, Inc</a>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>), a leader in genetic testing and precision medicine, today announced that its Prolaris prostate cancer prognostic test continues to be classified by the National Comprehensive Cancer Network (NCCN&#xAE;) as an ‘Advanced Tool' in the fight against prostate cancer1. Like other gene expression-based tests, Prolaris for many years has been included in NCCN guidelines with category 2A level of evidence, meaning its inclusion has support from at least 85% of members on the NCCN prostate panel2.

Myriad Genetics Announces NCCN Prostate Cancer Guidelines Reinforcing Status Of Myriad Genetics' Prolaris Test As An 'Advanced Tool' Recommended For Prognostic Assessment

Leerink Partners analyst Puneet Souda downgrades Myriad Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>) from Outperform to Market Perform and lowers the price target from $30 to $21.

Leerink Partners Downgrades Myriad Genetics to Market Perform, Lowers Price Target to $21

ILMN

Myriad Genetics Announces The Incorporation Of Its HRD Platform In Illumina's Updated Gene Panel Assay

Across the recent three months, 4 analysts have shared their insights on Myriad Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>), expressing a variety of opinions spanning from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $28.0, a high estimate of $35.00, and a low estimate of $21.00. This current average has decreased by 9.68% from the previous average price target of $31.00. 
<img src="https://www.benzinga.com/files/images/story/2024/1731938459_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Myriad Genetics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tejas Savant</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$21.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>John Peterson</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$24.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Tejas Savant</td>
<td>Morgan Stanley</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$32.00</td>
<td>-</td>
</tr>
<tr>
<td>Brandon Couillard</td>
<td>Wells Fargo</td>
<td>Announces</td>
<td>Overweight</td>
<td>$35.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Myriad Genetics. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Myriad Genetics compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Myriad Genetics's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/MYGN/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Myriad Genetics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>About Myriad Genetics</h2>
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.
<h3>Myriad Genetics's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Myriad Genetics displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 11.15%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Myriad Genetics's net margin excels beyond industry benchmarks, reaching -10.36%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Myriad Genetics's ROE excels beyond industry benchmarks, reaching -3.0%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Myriad Genetics's ROA excels beyond industry benchmarks, reaching -2.04%. This signifies efficient management of assets and strong financial health.
Debt Management: Myriad Genetics's debt-to-equity ratio stands notably higher than the industry average, reaching 0.2. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Where Myriad Genetics Stands With Analysts

Morgan Stanley analyst Tejas Savant maintains Myriad Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>) with a Equal-Weight and lowers the price target from $32 to $21.

Morgan Stanley Maintains Equal-Weight on Myriad Genetics, Lowers Price Target to $21

Sees Q4 revenue $209M-$211M, consensus $212.84M Published first on TheFly – the ultimate source for real-time, market-moving breaking financial new...

Myriad Genetics sees Q4 adjusted EPS 3c-4c, consensus 3c

Myriad Genetics expects Q4 revenues to be between $209M and $211M

In a report released today, Daniel Brennan from TD Cowen maintained a Hold rating on Myriad Genetics (MYGN – Research Report), with a price target ...

TD Cowen Sticks to Its Hold Rating for Myriad Genetics (MYGN)

Michael Ryskin, an analyst from Bank of America Securities, maintained the Sell rating on Myriad Genetics (MYGN – Research Report). The associated ...

Myriad Genetics: Sell Rating Maintained Amid Mixed Financial Outlook and Limited Catalysts

Myriad Genetics: Navigating Through A Setback

Myriad Genetics (MYGN) announced a study revealing that more patients completed hereditary cancer testing when they used an online screening tool a...

Myriad Genetics announces hereditary cancer risk assessment study published

In a report released yesterday, Puneet Souda from Leerink Partners maintained a Hold rating on Myriad Genetics (MYGN – Research Report), with a pri...

Leerink Partners Sticks to Their Hold Rating for Myriad Genetics (MYGN)

Myriad Genetics (MYGN) has launched a new educational website providing comprehensive information about reproductive and prenatal genetic testing. ...

Myriad Genetics introduces online prenatal genetic testing resource

Myriad Genetics (MYGN) announced it will unveil groundbreaking research at the annual Society for Maternal-Fetal Medicine, SMFM, conference. The co...

Myriad Genetics unveils resesrch at SMFM on cfDNA

Myriad Genetics (MYGN) and Lumea have signed an agreement to integrate Myriad's advanced molecular diagnostic tests – Prolaris Prostate Cancer Test...

Myriad Genetics announce collab with Lumea

Press Releases

Myriad Genetics to Present at 43rd Annual J.P. Morgan Healthcare Conference

UPDATE – Myriad Genetics to Present at 43rd Annual J.P. Morgan Healthcare Conference

Myriad Genetics Signs Agreement with Nationally Renowned Sports Broadcaster Hannah Storm to Promote the Importance of Knowing Family Cancer History

Myriad Genetics Announces Select Preliminary Fourth Quarter and Full Year 2024 Financial Results and Introduces Full Year 2025 Financial Guidance

Diligent Announces Market Insights Reporting Powered by S&P Global Market Intelligence, Giving Directors and Executives Unrivaled Financial and Risk Insights

Comments

Myriad Genetics

Myriad Genetics (MYGN) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL